NCT00094497 · OUTCOME

Progression-free Survival

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) · Source last updated 2016-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: every 8 weeks until progression or death up to 5 years

Groups in this outcome

EDP-M

etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)

Sz-M

streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
EDP-M	151
Sz-M	153

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
EDP-M	5.0	Not reported	3.5	6.9	Not reported
Sz-M	2.1	Not reported	2.04	2.33	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
3.5
upper Limit
6.9
value
5.0
group Id
OG001
lower Limit
2.04
upper Limit
2.33
value
2.1

denoms

counts
group Id
OG000
value
151
group Id
OG001
value
153
units
Participants

dispersion Type

95% Confidence Interval

groups

description
etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)
id
OG000
title
EDP-M
description
streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)
id
OG001
title
Sz-M

param Type

MEDIAN

reporting Status

POSTED

time Frame

every 8 weeks until progression or death up to 5 years

title

Progression-free Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice